7-(3-pyridyl)hept-6-enoic acid | 194159-71-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 7-(3-pyridyl)hept-6-enoic acid
• 英文别名: (E)-7-Pyridin-3-yl-hept-6-enoic acid；(E)-7-pyridin-3-ylhept-6-enoic acid
• CAS: 194159-71-2
• 化学式: C₁₂H₁₅NO₂
• 分子量: 205.257
• InChiKey: ONEHFHOVHUKWAG-ZZXKWVIFSA-N

物化性质

• 沸点：
  391.6±30.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(3-pyridyl)hept-6-enoic acid 在 镍 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 氨 、 水 、 氢气 、 sodium hydride 、 对甲苯磺酸 作用下， 以 甲醇 、 甲苯 为溶剂， 5.0~25.0 ℃ 、303.98 kPa 条件下， 反应 23.0h， 生成
  参考文献：
  名称：

  Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids

  摘要：

  A series of 8-[(arylsulfonyl)amino]octanoic acids substituted with a pyridinylalkyl group along the chain were synthesized and tested in vitro for their ability to both antagonize the binding of thromboxane A2 to its receptors and to inhibit the thromboxane synthase enzyme. This series of compounds were found to inhibit the U 46619-induced aggregation of human platelets and the U 46619-induced contraction of dog saphenous vein. The compounds also inhibited TxA2 biosynthesis in a human microsomal platelet preparation. The relative position of the pyridinylalkyl and arylsulfonamido groups had significant effects on the thromboxane receptor antagonist (TxRA) activity and thromboxane synthase inhibitor (TxSI) activity. Compounds with the pyridine ring at the 7- or 8-position of the octanoic acid side chain were weakly active as TxSI but behaved as potent TxRA at the platelet receptor for TxA2. However, these compounds were agonists at the vascular receptor. Substitution of the pyridinylalkyl group at the 2- or 3-position resulted in compounds with potent TxSI activity and weak TxRA activity. The activity profile of the compounds with the pyridinylalkyl substitution at the 4-, 5-, or 6-position was very desirable. Compound 22 with a pyridinylpropyl substituent at the 4-position was found to display extremely potent TxRA and TxSI properties.

  DOI：

  10.1021/jm00101a014
• 作为产物：
  描述：

  methyl 7-(3-pyridinyl)hept-6-enoate 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 methanolic hydrochloric acid 、 水 、 丙酮 为溶剂， 生成 7-(3-pyridyl)hept-6-enoic acid
  参考文献：
  名称：

  (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and

  摘要：

  揭示了以下式的化合物##STR1##其中A代表较低的烷基; B代表氧、硫、较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基、苯基或直接键; M代表较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基或直接键; 或者A、B和M中的一个代表较低的烷基亚烯基，另外两个独立地代表较低的烷基; R代表氢，除非A、B或M代表较低的烷基亚烯基，在这种情况下R代表相邻烷基亚烯基不饱和碳原子的第二键; Het代表1-咪唑基、3-吡啶基，或者被较低烷基取代的1-咪唑基或3-吡啶基; Ar代表碳环或杂环芳基; 其药学上可接受的酯和酰胺衍生物; 其中Het代表可选择取代的吡啶基的N-氧化物; 公式I中COOH被5-四唑基取代的所述化合物; 和药学上可接受的盐; 这些化合物可用作血栓素合酶抑制剂和血栓素受体拮抗剂。

  公开号：

  US05025025A1

文献信息

• (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and
  申请人：Ciba-Geigy Corporation

  公开号：US05025025A1

  公开（公告）日：1991-06-18

  Disclosed are the compounds of formula ##STR1## wherein A represents lower alkylene; B represents oxygen, sulfur, lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl-, sulfonyl- or thio)-lower alkylene, lower alkenylene, phenylene or a direct bond; M represents lower alkylene, lower alkylene interrupted by oxygen, sulfur, sulfinyl or sulfonyl, (oxy-, sulfinyl, sulfonyl- or thio)-lower alkylene, lower alkenylene or a direct bond; or one of A, B and M represents lower alkylidenylene and the other two independently represent lower alkylene; R represents hydrogen unless A, B or M represents lower alkylidenylene in which case R represents the second bond to the adjacent aklylidenylene unsaturated carbon atom; Het represents 1-imidazolyl, 3-pyridyl, or 1-imidazolyl or 3-pyridyl substituted by lower alkyl; Ar represents carbocyclic or heterocyclic aryl; pharmaceutically acceptable ester and amide derivatives thereof; the N-oxides of said compounds wherein Het represents optionally substituted pyridyl; the said compounds of formula I wherein COOH is replaced by 5-tetrazolyl; and the pharmaceutically acceptable salts; which are useful as thromboxane synthetase inhibitors and thromboxane receptor antagonists.

  揭示了以下式的化合物##STR1##其中A代表较低的烷基; B代表氧、硫、较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基、苯基或直接键; M代表较低的烷基、被氧、硫、亚砜或磺酰中断的较低的烷基、(氧基、亚砜基、磺酰基或硫基)-较低的烷基、较低的烯基或直接键; 或者A、B和M中的一个代表较低的烷基亚烯基，另外两个独立地代表较低的烷基; R代表氢，除非A、B或M代表较低的烷基亚烯基，在这种情况下R代表相邻烷基亚烯基不饱和碳原子的第二键; Het代表1-咪唑基、3-吡啶基，或者被较低烷基取代的1-咪唑基或3-吡啶基; Ar代表碳环或杂环芳基; 其药学上可接受的酯和酰胺衍生物; 其中Het代表可选择取代的吡啶基的N-氧化物; 公式I中COOH被5-四唑基取代的所述化合物; 和药学上可接受的盐; 这些化合物可用作血栓素合酶抑制剂和血栓素受体拮抗剂。
• Compounds and inhibitors of phospholipases
  申请人：——

  公开号：US20040033995A1

  公开（公告）日：2004-02-19

  The present invention relates generally to amino acid derivatives and to methods of making the same. In particular, the invention relates to compounds bearing a stereochemical identity, that is, the same stereochemistry, with the chiral &agr;-carbon of D-&agr;-amino acids and their use in methods of therapy, including the treatment of inflammatory diseases, and to compositions and enantiomeric mixtures containing them.

  本发明一般涉及氨基酸衍生物及其制备方法。具体而言，该发明涉及具有立体化学特性的化合物，即与D-α-氨基酸的手性α-碳具有相同立体化学的化合物，以及它们在治疗方法中的应用，包括治疗炎症性疾病，以及含有它们的组合物和对映体混合物。
• [EN] COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES<br/>[FR] COMPOSES ET INHIBITEURS DE PHOSPHOLIPASES
  申请人：UNIV QUEENSLAND

  公开号：WO2002008189A1

  公开（公告）日：2002-01-31

  The present invention relates generally to amino acid derivatives and to methods of making the same. In particular, the invention relates to compounds bearing a stereochemical identity, that is, the same stereochemistry, with the chiral α-carbon of D-α-amino acids and their use in methods of therapy, including the treatment of inflammatory diseases, and to compositions and enantiomeric mixtures containing them.

  本发明通常涉及氨基酸衍生物及其制备方法。特别地，本发明涉及具有立体化学同一性的化合物，即具有D-α-氨基酸的手性α-碳的同一立体化学，以及它们在治疗方法中的使用，包括治疗炎症性疾病，以及含有它们的组合物和对映体混合物。
• Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof
  申请人：CIBA-GEIGY AG

  公开号：EP0405391A1

  公开（公告）日：1991-01-02

  The present invention is concerned with compounds of formula I wherein A, B, M, R, Ar and Het are as defined in the specification, pharmaceutically acceptable ester and amide derivatives thereof; N-oxides thereof, tetrazole derivatives thereof, and salts thereof. These compounds have valuable pharmacological activities, especially as inhibitors of thromboxane synthetase and as receptor antagonists of thromboxane A₂ and prostaglandin H₂. They are prepared in a manner known per se.

  本发明涉及式 I 化合物（其中 A、B、M、R、Ar 和 Het 如说明书中所定义）、其药学上可接受的酯和酰胺衍生物、其 N-氧化物、其四唑衍生物及其盐类。 这些化合物具有重要的药理活性，特别是作为血栓素合成酶的抑制剂和血栓素 A₂及前列腺素 H₂的受体拮抗剂。 它们的制备方法本身是已知的。
• KATO, KANEYOSHI;OHKAWA, SHIGENORI;TERAO, SHINJI;TERASHITA, ZEN-ICHI;NISHI+, J. MED. CHEM., 1985, 28, N 3, 287-294
  作者：KATO, KANEYOSHI、OHKAWA, SHIGENORI、TERAO, SHINJI、TERASHITA, ZEN-ICHI、NISHI+

  DOI：——

  日期：——